Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 177-185

  Qiao, Jing ^a,b   Zhang, Qinglin ^a   Li, Ming ^b  

^a SOUTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Adolescence; Clozapine; Conditioned avoidance response; Olanzapine; Risperidone; Sensitization

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENCE; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIZATION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; SPRAGUE DAWLEY RAT; STARTLE REFLEX;

% PPI; 5′-BROMO-2-DEOXYURIDINE; ADOLESCENCE; BRDU; CAR; CLOZAPINE; CLOZAPINE 5.0 MG/KG; CLZ; CLZ 5.0; CONDITIONED AVOIDANCE RESPONSE; CONDITIONED STIMULUS; CS; DA; DOPAMINE; FDA; FOOD AND DRUG ADMINISTRATION; GABA; GAMMA AMINO BUTYRIC ACID; OLANZAPINE; OLANZAPINE 0.5 MG/KG; OLZ; OLZ 0.5; P; PCP; PERCENT PREPULSE INHIBITION; PFC; PHENCYCLIDINE; POSTNATAL; PPI; PREFRONTAL CORTEX; PREPULSE INHIBITION; RIS; RIS 1.0; RISPERIDONE; RISPERIDONE 1.0 MG/KG; SC; SENSITIZATION; SUBCUTANEOUSLY; UNCONDITIONED STIMULUS; US; VEH; VEHICLE;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INHIBITION (PSYCHOLOGY); MALE; RATS; RATS, SPRAGUE-DAWLEY; REFLEX, ACOUSTIC; RISPERIDONE; TIME; TIME FACTORS;

EID: 84886380556     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.10.005     Document Type: Article

References (57)

1. Addy N., Levin E.D. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 2002, 27:534-541.
2. Andersen S.L., Thompson A.T., Rutstein M., Hostetter J.C., Teicher M.H. Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse 2000, 37:167-169.
3. Burke A.R., Watt M.J., Forster G.L. Adolescent social defeat increases adult amphetamine conditioned place preference and alters D2 dopamine receptor expression. Neuroscience 2011, 197:269-279.
4. Chen J., Wang Z., Li M. Multiple 'hits' during postnatal and early adulthood periods disrupt the normal development of sensorimotor gating ability in rats. J Psychopharmacol 2011, 25:379-392.
5. Choi Y.K., Moran-Gates T., Gardner M.P., Tarazi F.I. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol 2010, 20:187-194.
6. Culm K.E., Hammer R.P. Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats. J Pharmacol Exp Ther 2004, 308:487-494.
7. Davis J.M., Leucht S. Commentary on strategies for switching antipsychotics. BMC Med 2008, 6:18.
8. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., Lieberman J.A. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006, 163:2090-2095.
9. Feng M., Sui N., Li M. Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm. Behav Brain Res 2012, 238C:178-187.
10. Feng M., Sui N., Li M. Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm. Behav Brain Res 2013, 238:178-187.
11. Findling R.L., Johnson J.L., McClellan J., Frazier J.A., Vitiello B., Hamer R.M., et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010, 49:583-594. [quiz 632].
12. Gardos G. Are antipsychotic drugs interchangeable?. J Nerv Ment Dis 1974, 159:343-348.
13. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
14. Koller W., Herbster G., Herbster G., Wack R., Gordon J. Quinpirole hydrochloride, a potential anti-parkinsonism drug. Neuropharmacology 1987, 26:1031-1036.
15. Koob G.F., Simon H., Herman J.P., Le Moal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems. Brain Res 1984, 303:319-329.
16. Kumra S., Oberstar J.V., Sikich L., Findling R.L., McClellan J.M., Vinogradov S., et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008, 34:60-71.
17. Li M., Fletcher P.J., Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007, 32:263-272.
18. Li M., He W., Mead A. An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav Pharmacol 2009, 20:184-194.
19. Li M., He W., Mead A. Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 2009, 20:84-98.
20. Li M., Sun T., Zhang C., Hu G. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 2010, 212:45-57.
21. Li M., He E., Volf N. Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 2011, 98:559-569.
22. Li M., He W., Chen J. Time course of prepulse inhibition disruption induced by dopamine agonists and NMDA antagonists: effects of drug administration regimen. Pharmacol Biochem Behav 2011, 99:509-518.
23. Li M., Sun T., Mead A. Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT2A/2C receptors. J Neural Transm 2012, 119:497-505.
24. Li M., Sun T., Mead A. Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A/2C) receptors. J Neural Transm 2012, 119:497-505.
25. Llorente-Berzal A., Mela V., Borcel E., Valero M., Lopez-Gallardo M., Viveros M.P., et al. Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats. Neuropharmacology 2012, 62:1332-1341.
26. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-610.
27. Mead A., Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 2010, 24:1045-1053.
28. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
29. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
30. Meyer U., Spoerri E., Yee B.K., Feldon J. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull 2010, 36:607-623.
31. Millan M.J., Brocco M., Gobert A., Joly F., Bervoets K., Rivet J., et al. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999, 11:4419-4432.
32. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
33. Moran-Gates T., Gan L., Park Y.S., Zhang K., Baldessarini R.J., Tarazi F.I. Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse 2006, 59:92-100.
34. Overton D.A. Preclinical measurement of the amount of state-dependent learning produced by psychoactive drugs [proceedings]. Psychopharmacol Bull 1979, 15:51-52.
35. Patel N.C., Crismon M.L., Hoagwood K., Johnsrud M.T., Rascati K.L., Wilson J.P., et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005, 44:548-556.
36. Piontkewitz Y., Arad M., Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2011, 37:1257-1269.
37. Porter J.H., Prus A.J. Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies. Psychopharmacology (Berl) 2009, 203:279-294.
38. Prosser E.S., Pruthi R., Csernansky J.G. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology (Berl) 1989, 99:109-116.
39. Qiao J., Li H., Li M. Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology 2013, 38:513-524.
40. Qin R., Chen Y., Li M. Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. Neuropharmacology 2013, 75C:356-364.
41. Rosenheck R.A., Davis S., Covell N., Essock S., Swartz M., Stroup S., et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res 2009, 107:22-29.
42. Schechter M.D., Cook P.G. Dopaminergic mediation of the interoceptive cue produced by d-amphetamine in rats. Psychopharmacologia 1975, 42:185-193.
43. Shu Q., Hu G., Li M. Is brain-derived neurotrophic factor a possible mechanism underlying risperidone sensitization in adolescent rats. Biochem Pharmacol 2013, S1:004.
44. Shu Q., Hu G., Li M. Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol 2013, [accepted for publication].
45. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431.
46. Singh M.K., Chang K.D. The neural effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr Clin N Am 2012, 21:753-771.
47. Sun T., Hu G., Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 2009, 602:334-342.
48. Sun T., He W., Hu G., Li M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 2010, 95:298-307.
49. Swalve N., Li M. Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol 2012, 23:380-391.
50. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000, 11:185-204.
51. Teicher M.H., Andersen S.L., Hostetter J.C. Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res Dev Brain Res 1995, 89:167-172.
52. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
53. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev 1999, 23:851-862.
54. Wadenberg M.L., Ericson E., Magnusson O., Ahlenius S. Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiatry 1990, 28:297-307.
55. White I.M., Rebec G.V. Responses of rat striatal neurons during performance of a lever-release version of the conditioned avoidance response task. Brain Res 1993, 616:71-82.
56. Zhang C., Li M. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol 2012, 23:66-79.
57. Zhang C., Fang Y., Li M. Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence. Pharmacol Biochem Behav 2011, 98:155-160.